Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05587478 · ClinicalTrials.gov registry record · Phase 1
A Study of EDP-323 in Healthy Subjects
A Phase 1 study of RSV Infection, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT05587478: Completed Phase 1 study of RSV Infection, sponsored by Enanta Pharmaceuticals.
NCT05587478 is a Phase 1 study of RSV Infection that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 82 participants, below the 737-participant average among 8 other RSV Infection trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05587478, a Phase 1 study of RSV Infection, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EDP-323
Study Locations (1)
Kansas
- ICON, plc. - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2022-09-29 |
| Est. Completion | 2023-03-29 |
| Phase | Phase 1 |
What the finished NCT05587478 record still lists
NCT05587478 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 737-participant average among 8 other RSV Infection trials with a reported enrollment target (89% lower).
The record links to 1 condition, with RSV Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05587478 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT05587478 about?
NCT05587478 is a clinical study titled "A Study of EDP-323 in Healthy Subjects". This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.
What is the current status of trial NCT05587478?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2022-09-29. Estimated completion is 2023-03-29.
What conditions does trial NCT05587478 study?
This clinical trial studies the following conditions: RSV Infection.
What interventions are being tested in trial NCT05587478?
The interventions under investigation include: Placebo (DRUG), EDP-323 (DRUG).
Who is sponsoring clinical trial NCT05587478?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05587478 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RSV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05587478's enrollment target sits among peer trials
82 6th of 8 higher than 3 of 8 other RSV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other RSV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
RECRUITING · Phase 1
-
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
COMPLETED · Phase 1
-
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
RECRUITING · Phase 3
-
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
RECRUITING
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI